CGM Procurement Guide: OEM/ODM Technical Files for Continuous Glucose Monitoring

Short answer: what you are really buying in a CGM system

Buying continuous glucose monitoring is not like buying gauze or gloves, because a CGM system is three coordinated components rather than one box: a subcutaneously implanted glucose sensor, a wireless transmitter, and a handheld receiver or smartphone app. The commercial value sits in the combination — sensor chemistry that holds its performance across the full wear period, transmitter electronics, and the software that turns a stream of readings into trends, arrows and alarms. The Artemisine CGMS pairs a factory-calibrated 14-day wearable sensor with a transmitter and app, streaming glucose readings every few minutes with high and low alarms, and requires no routine fingerstick calibration.

For a buyer that means one purchase order covers three different products: an expiry-dated sensor consumable, an electronic transmitter, and a software ecosystem the patient will live in daily. On top of the hardware sits a fourth, invisible component — the technical file of risk analysis, biocompatibility and software verification evidence that decides whether the system can be registered in your market at all. This guide sets out what to specify at each layer when sourcing CGM systems factory-direct, with particular attention to the OEM/ODM and technical-file questions that dominate device procurement timelines.

Step one: specify the system, not just the sensor

Write the tender around components, not categories. A usable CGM specification states the sensor wear duration — the Artemisine sensor is typically worn for 7 to 14 days, with 14 days as the standard wear for the factory-calibrated sensor — and states the calibration profile explicitly: factory-calibrated means the user performs no routine fingerstick calibration against a blood glucose meter. It states how often readings stream to the receiver (the Artemisine system reports every few minutes), what the alarm behaviour is (high and low glucose alerts with trend information), and which receiver the market will use: a handheld monitor, a smartphone app, or both, including data sharing for caregivers.

Two specification details are routinely missed. First, the app: confirm the display language and whether readings can be shared with a clinic or family member — this is a purchasing decision, not a feature note. Second, the receiver decision drives cost per patient: a handheld receiver adds hardware to every tender line, while an app-based system relies on the patient's own phone. Naming these choices in the tender is what turns a CGM quotation from a price per box into a comparable programme cost.

Step two: define the OEM/ODM scope before the first order

Most CGM buyers are not importing under the manufacturer's brand — they are building their own. The Artemisine CGM is offered factory-direct with OEM/ODM options: a private-label app, localized language packs, market-specific packaging, and the technical documentation needed to register the system under the distributor's own name.

Treat the OEM/ODM scope as a specification in its own right, agreed before quoting. In practice that means four items in writing: the brand name and label artwork that will appear on sensor, transmitter and packaging; the list of app languages for the target market; the packaging configuration — bottle, blister or box, customised per market requirement; and who owns the adapted regulatory documentation once the dossier carries your brand. Defining these early prevents the most common OEM/ODM failure mode: a first shipment that cannot be sold because the label, the language or the pack does not match the registration you filed.

Step three: demand the technical file with the quotation

The component that decides whether a CGM programme launches on schedule is not the sensor — it is the technical file. The Artemisine CGM is supported by complete technical files covering risk analysis, biocompatibility and software verification, structured for CE-style submissions and national registrations.

Demand the dossier with the quotation, not after the purchase order. A registration review typically runs months longer than the manufacturing lead time, so the file, not the factory, sits on the critical path. Before committing, check the file against your own national requirements — markets differ in what they accept for software documentation and biocompatibility evidence — and confirm which documents travel with each batch: the Artemisine documentation set includes COA, COPP, DMF and CTD-format dossiers alongside the device technical file. A supplier that puts the complete file on the table at quotation stage is a supplier whose registration timelines you can plan around.

Step four: audit the quality system behind the device

A CGM system is part consumable chemistry and part electronics, so the quality question is broader than for a drug product. Sensor performance depends on manufacturing consistency — the same chemistry and membrane, batch after batch — while the transmitter and app depend on disciplined software lifecycle control. Artemisine manufactures under WHO GMP-aligned environmental monitoring, and the technical file is maintained alongside that quality system rather than assembled ad hoc for each customer.

When auditing a CGM supplier, ask three questions. How is batch consistency demonstrated — which certificates and batch documentation cover each lot? How are software changes controlled and communicated — an app update can change alarm behaviour, and regulators increasingly care? And how are field complaints and returns handled? The answers tell you whether you are buying from a manufacturer with a documented quality system or from a trading company repackaging someone else's device.

Step five: plan shelf life and logistics like a pharmaceutical buyer

CGM sensors are expiry-dated goods: the sensor ages whether or not the box is opened, so device procurement has to plan like pharmaceutical procurement. At quotation stage, confirm the remaining shelf life on the offered batch, the storage conditions, and the minimum remaining life your market requires at import — a discounted batch with six months left can be unsellable.

Packaging is market-specific by design, so label artwork lead time belongs inside the delivery schedule, not after it. And because the system combines body-worn sensors with electronics, confirm how the components pair: sensors, transmitters and receivers are typically quoted as one programme, and mismatched quantities of any single component strand inventory. The batch documentation travels with the shipment, so customs and receiving inspection see the same file you audited.

Bundle CGM with the diabetes portfolio

A CGM programme is strongest when it is sold as part of a diabetes-care supply chain rather than as a standalone gadget. Artemisine bundles the CGM with its injectable insulin portfolio — human insulin, isophane and glargine presentations — and its GLP-1 pen range, so a distributor can tender a complete diabetes management programme from a single manufacturer.

The sourcing logic behind a bundle is documented in two companion guides: our comparison of factory-direct versus branded-import insulin sourcing and the GLP-1 procurement guide. The same questions — who holds the dossier, who controls cold chain for the medicine lines, who answers a field complaint — apply to the device line. Bundling also simplifies the commercial side: one quotation, one documentation set per programme, and a single escalation path when something goes wrong in market.

MOQ, lead time, and how to inquire

Artemisine answers inquiries within 24 hours and issues exact quotations against a named product, quantity, pack configuration and destination market. The useful first message therefore names the sensor system, the receiver model, the OEM/ODM scope and the target registration market — not simply "CGM price". With that information, stock position, MOQ, dated lead time and dossier availability are confirmed against a real requirement, and the technical file and batch documentation are attached to the quotation rather than promised after the first shipment. Start the conversation through the contact page.

Frequently asked questions

Source: summarised from Artemisine CGM technical documentation — risk analysis, biocompatibility and software verification files — under WHO GMP-aligned environmental monitoring. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.